424 related articles for article (PubMed ID: 17895513)
1. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
Naumnik B; Pawlak K; Mys'liwiec M
Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
[TBL] [Abstract][Full Text] [Related]
2. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
Naumnik B; Pawlak K; Myśliwiec M
Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
[TBL] [Abstract][Full Text] [Related]
3. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
Naumnik B; Borawski J; Myśliwiec M
Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
[TBL] [Abstract][Full Text] [Related]
4. Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study.
Naumnik B; Pawlak K; Myśliwiec M
Cytokine; 2007 Nov; 40(2):98-104. PubMed ID: 17920287
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.
Naumnik B; Borawski J; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2007 Jun; 22(6):1690-6. PubMed ID: 17389624
[TBL] [Abstract][Full Text] [Related]
6. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
Klejna K; Naumnik B; Koc-Żórawska E; Myśliwiec M
Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
[TBL] [Abstract][Full Text] [Related]
7. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
[TBL] [Abstract][Full Text] [Related]
8. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
[TBL] [Abstract][Full Text] [Related]
9. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
[TBL] [Abstract][Full Text] [Related]
10. Over-dialysis plasma RANTES increase depends on heparin dose and cardiovascular disease status.
Naumnik B; Koc-Żórawska E; Myśliwiec M
Adv Med Sci; 2013; 58(2):311-9. PubMed ID: 23959669
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis.
Aggarwal A; Whitaker DA; Rimmer JM; Solomon RJ; Gennari FJ; Sobel BE; Schneider DJ
Nephrol Dial Transplant; 2004 Jun; 19(6):1559-63. PubMed ID: 15034156
[TBL] [Abstract][Full Text] [Related]
12. Is dialysis membrane type responsible for increased circulating adhesion molecules during chronic hemodialysis?
Mrowka C; Heintz B; Sieberth HG
Clin Nephrol; 1999 Nov; 52(5):312-21. PubMed ID: 10584995
[TBL] [Abstract][Full Text] [Related]
13. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
Cugno M; Mari D; Meroni PL; Gronda E; Vicari F; Frigerio M; Coppola R; Bottasso B; Borghi MO; Gregorini L
Br J Haematol; 2004 Jul; 126(1):85-92. PubMed ID: 15198737
[TBL] [Abstract][Full Text] [Related]
14. Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients.
Grooteman MP; Gritters M; Wauters IM; Schalkwijk CG; Stam F; Twisk J; Ter Wee PM; Nubé MJ
Nephrol Dial Transplant; 2005 Dec; 20(12):2751-8. PubMed ID: 16188898
[TBL] [Abstract][Full Text] [Related]
15. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
[TBL] [Abstract][Full Text] [Related]
17. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
19. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin.
Borawski J; Naumnik B; Myśliwiec M
Kidney Int; 2003 Dec; 64(6):2229-37. PubMed ID: 14633147
[TBL] [Abstract][Full Text] [Related]
20. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
